Boiron announces the signature of a disposal agreement, under the terms of the exclusive agreement announced in July 2023, for the transfer of all Boiron shares held by the family concert to Boiron Développement.
This transfer, if the final conditions are met, should be followed by the filing of a proposed simplified tender offer (OPAS) for the Boiron shares and, if the conditions are met at the end of this offer, a squeeze-out.
The sale agreement sets out the principle and conditions of the transfer, by way of contribution in kind and sale, of 12,255,758 Boiron shares, representing 69.85% of the share capital and 78.06% of the theoretical voting rights, on the basis of the same price as that of the offer.
As a reminder, Boiron Développement's public stock buyback tender offer would be made at a price of €39.64 per share, less an exceptional dividend of €10.36 per share subject to approval by the AGM convened for October 16.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).